Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Legend Biotech ( (LEGN) ) has shared an update.
On March 10, 2026, Legend Biotech reported its fourth quarter and full-year 2025 results, highlighting CARVYKTI net trade sales of about $555 million in the quarter and $1.9 billion for the year, and announcing that more than 10,000 patients had been treated globally. The company said CARVYKTI achieved franchise profitability in 2025, expanded availability to 14 markets and 294 sites, strengthened manufacturing with an enlarged Raritan facility capable of supplying up to 10,000 patients annually, and improved operating performance enough to post positive adjusted net income in the quarter while ending the year with $949 million in cash and equivalents, supporting its aim to reach company-wide operating profit beyond 2026.
Legend also underscored strategic investments in its pipeline and infrastructure, including opening a 31,000-square-foot R&D center in Philadelphia, dosing the first patients with in vivo candidates, and presenting encouraging first-in-human data for its allogeneic CAR-T LUCAR-G39D in B-cell non-Hodgkin lymphoma. While reported net income for the quarter swung to a $30.9 million loss, mainly due to unrealized foreign exchange movements rather than underlying operations, the results reinforced Legend’s growing commercial scale in multiple myeloma, its rising role as a leading cell therapy manufacturer, and its capacity to fund continued innovation and expansion for the benefit of patients, partners and investors.
The most recent analyst rating on (LEGN) stock is a Buy with a $80.00 price target. To see the full list of analyst forecasts on Legend Biotech stock, see the LEGN Stock Forecast page.
Spark’s Take on LEGN Stock
According to Spark, TipRanks’ AI Analyst, LEGN is a Neutral.
The score is most constrained by weak financial performance (ongoing losses and negative operating/free cash flow) and bearish technicals (price below major moving averages with negative MACD). These are partially offset by a positive earnings-call outlook driven by strong CARVYKTI growth, expanding international demand, and improved labeling that could support the path to profitability.
To see Spark’s full report on LEGN stock, click here.
More about Legend Biotech
Legend Biotech Corporation is a global cell therapy company headquartered in Somerset, N.J., and listed on Nasdaq under the ticker LEGN. Focused on CAR-T treatments for cancer, it co-develops and markets CARVYKTI, a one-time therapy for relapsed or refractory multiple myeloma, with Johnson & Johnson, while building an end-to-end cell therapy platform and advancing a diversified pipeline of in vivo and allogeneic programs.
Average Trading Volume: 2,439,268
Technical Sentiment Signal: Sell
Current Market Cap: $3.53B
See more data about LEGN stock on TipRanks’ Stock Analysis page.